Infinity Pharmaceuticals initiated with a Buy at Seaport Global. Seaport Global analyst Corey Davis initiated Infinity Pharmaceuticals with a Buy and $4 price target. The analyst believes 2018 could be a "break-out" year with new data on its lead compound IPI-549 in combination with Opdivo for various tumor types with June 4 at ASXO form its "dose escalation" cohort, Q2 initial data from the "dose expansion" cohort, and more mature data from the "dose expansion" later in the year.
https://bit.ly/2stYlXW
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.